Awasthi, A., Rolland, D. C., Ayello, J., van de Ven, C., Basrur, V., Conlon, K., . . . Cairo, M. S. (2017). A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget.
Citación estilo ChicagoAwasthi, Aradhana, et al. "A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathway Proteins After Treatment." Oncotarget 2017.
Cita MLAAwasthi, Aradhana, et al. "A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathway Proteins After Treatment." Oncotarget 2017.